BRAF and duodenal adenocarcinoma: On the other hand, the 45 patients with early-stage duodenal adenocarcinoma showed significant differences in anatomical location (P = 0.04), treatment methods (P < 0.01), tumor histology (P < 0.01), BRAF mutation (P = 0.01), mucin phenotype (P < 0.01), and PD-L1 status (P < 0.01) compared with the 48 patients with advanced-stage duodenal adenocarcinoma (Table 1).